What is the appropriate evaluation and management of cough in a pregnant patient?

Evaluation and Management of Cough in Pregnancy

Maintain asthma control during pregnancy with albuterol and inhaled corticosteroids (preferably budesonide), as it is safer to treat asthma than to have uncontrolled symptoms that risk perinatal mortality, pre-eclampsia, preterm birth, and low-birth-weight infants. 1

Initial Assessment: Rule Out Serious Pathology

Red-Flag Symptoms Requiring Immediate Chest Radiography

• Hemoptysis, fever >4 days, new focal chest signs (crackles, diminished breath sounds), dyspnea, tachypnea, or weight loss mandate chest X-ray to exclude pneumonia, tuberculosis, or malignancy 2, 3
• Radiation exposure from chest radiography poses minimal fetal risk and should not be withheld when clinically indicated 1, 3
• Delayed diagnosis of tuberculosis in pregnancy has caused fatal outbreaks; obtain chest X-ray, sputum culture, and IGRA testing when TB symptoms or high-risk factors are present 3

Common Etiologies of Cough in Pregnancy

• Gastroesophageal reflux disease accounts for 77% of cough in pregnant women without bronchial pathology, with reflux-induced laryngeal changes documented in 97% of cases 4
• Emerging asthma (12%), sluggish bronchitis (7%), and allergic rhinitis (4%) comprise the remaining causes 4
• Cough duration correlates with gestational age, reflecting physiologic changes that exacerbate reflux and airway reactivity 4

Diagnostic Approach by Duration

Acute Cough (<3 Weeks): Viral Upper Respiratory Infection

• Most acute coughs are viral and self-limited, resolving within 2 weeks without antibiotics 1, 2
• Supportive care with guaifenesin 200–400 mg every 4 hours (maximum 6 doses daily), honey with lemon, adequate hydration, and head-elevated sleeping is appropriate initial management 2, 5
• Antibiotics provide no benefit for viral bronchitis, increase resistance, and risk adverse effects including C. difficile infection 2, 5

Subacute Cough (3–8 Weeks): Post-Infectious Cough

• Inhaled ipratropium bromide 2–3 puffs four times daily is first-line therapy, with the strongest evidence for reducing post-infectious cough and response expected within 1–2 weeks 2, 5
• If cough persists despite ipratropium and impairs quality of life, add inhaled corticosteroid (fluticasone 220 µg or budesonide 360 µg twice daily), allowing up to 8 weeks for full effect 2, 5
• Oral prednisone 30–40 mg daily for 5–10 days is reserved for severe paroxysmal cough only after excluding upper-airway cough syndrome, asthma, and GERD 2, 5

Chronic Cough (>8 Weeks): Systematic Evaluation Required

• Systematically evaluate for upper airway cough syndrome (UACS), asthma, and GERD, as these account for the majority of chronic cough cases 5, 6, 7
• Obtain spirometry with bronchodilator response to identify reversible airway obstruction; cough-variant asthma accounts for 24–32% of chronic cough 6, 7
• Consider bronchoprovocation challenge (methacholine) when spirometry is normal but asthma remains suspected 6, 7

Management of Asthma in Pregnancy

Medication Safety Profile

• Albuterol is the preferred short-acting beta-agonist, with the most reassuring human pregnancy safety data 1
• Budesonide is the preferred inhaled corticosteroid due to extensive pregnancy safety data, though no evidence indicates other ICS preparations are unsafe 1
• Monthly asthma evaluations allow timely step-up or step-down therapy, as asthma improves in one-third and worsens in one-third of pregnant women 1

Treatment Principles

• Maintaining lung function is critical to ensure fetal oxygen supply; uncontrolled asthma increases risk of perinatal mortality, pre-eclampsia, preterm birth, and low-birth-weight infants 1
• It is safer to treat asthma with medications than to have symptoms and exacerbations during pregnancy 1

Management of GERD-Related Cough

• Initiate high-dose PPI therapy (omeprazole 40 mg twice daily) with dietary modifications when GERD is suspected, even without typical GI symptoms 5
• Response to PPI therapy may require 2 weeks to several months, necessitating patient counseling about delayed improvement 5

Management of Upper Airway Cough Syndrome

• Prescribe first-generation antihistamine-decongestant combination (e.g., chlorpheniramine/phenylephrine) plus intranasal corticosteroid spray (fluticasone or mometasone) for UACS 5
• Improvement typically occurs within days to 1–2 weeks of initiating therapy 5

Special Consideration: Pertussis

• Suspect pertussis when cough lasts ≥2 weeks with paroxysms, post-tussive vomiting, or inspiratory "whoop" 5, 8
• Obtain nasopharyngeal swab and start empiric macrolide therapy (azithromycin or clarithromycin) without awaiting results 8
• Isolate patient for 5 days after starting antibiotics to prevent transmission 8

Community-Acquired Pneumonia in Pregnancy

When to Suspect Pneumonia

• New focal chest signs, dyspnea, tachypnea, heart rate >100 bpm, or fever >4 days raise suspicion for pneumonia 9
• Obtain chest radiograph immediately when clinical suspicion is present; reliance on clinical features alone is insufficient 9

Antibiotic Selection

• Beta-lactam antibiotics (amoxicillin) and macrolides (azithromycin, clarithromycin) are first-line agents, providing appropriate pathogen coverage (S. pneumoniae, H. influenzae, M. pneumoniae) and pregnancy safety 9
• Trimethoprim/sulfamethoxazole remains the treatment of choice for Pneumocystis pneumonia in HIV-infected pregnant patients despite theoretical risks, as mortality remains high without treatment 9

Common Pitfalls to Avoid

• Do not prescribe antibiotics for post-infectious cough or viral bronchitis, as they provide no benefit and contribute to resistance 2, 5
• Do not delay chest radiography in pregnant women with concerning symptoms due to unfounded radiation fears; delayed TB diagnosis has caused fatal outbreaks 3
• Do not fail to recognize when post-infectious cough persists beyond 8 weeks, requiring reclassification as chronic cough and systematic evaluation 5
• Do not withhold asthma medications during pregnancy; uncontrolled asthma poses greater fetal risk than medication exposure 1